Nordic Nanovector - Fundamentale forhold 2019 (NANO)

[soprano]

Fra spøk til alvor. At nano har frafall på 5 (7%) pasienter i Lymrit 37-01 i en populasjon med median-alder på over 65, er svært imponerende.

Sammenligner man med f.eks REGN1979 studiet som det skrives om ovenfor, så frafaller jo 60% av pasientene (40% grunnet progressive disease, 20% av andre ymse årsaker).

[pdx]

Tilbake til topic

[soprano]

@pdx, enig i at den spøken var litt i grenseland, men off topic var den absolutt ikke. Ettersom beskyttet sex er ett av kriteriene for å delta i studiet, så er det faktisk ikke helt utenkelig at noen av de 5 som har frafalt var “uforsiktige”. Selvsagt andre grunner som trolig er mer sannsynlig, men med mindre noen fant innlegget mitt usømmelig og støtende, så synes jeg ikke det var noen grunn til å vifte med diktatorstokken

[sparkonge]

Helt korrekt. Det var et innlegg jeg smilte av

(Så er det selvsagt forståelig at @pdx “ikke tok spøken” ettersom det fordrer forholdvis inngående kunnskap til inklusjon- og eksklusjon skriteriene.)

[TekBot]

04/12-2018 03:01:12: (NANO) Nordic Nanovector: Additional preclinical studies with CD37-targeting radioimmunotherapies for B-cell malignancies presented at ASH

Oslo, Norway, 4 December 2018

Nordic Nanovector ASA (OSE: NANO) notes that two new poster presentations from
…

Vis børsmeldingen

preclinical studies with CD37-targeting radioimmunotherapies were made at the
60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4
December 2018 in San Diego, CA, USA). These posters were presented in addition
to the results of the Phase 1/2 trial of Betalutin® (177Lu-satetraxetan
-lilotomab) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma

• see separate announcement.

The posters are as follows:

Abstract 4422

Abstract title:

Targeted Alpha Therapy with 212Pb-NNV-003 for the Treatment of CD37 Positive B
-Cell Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)

Authors:

A. Saidi et al.

This poster describes results from a research collaboration to develop a novel
CD37-targeting alpha therapy for B-cell malignancies and the results noted in
the abstract were previously announced on 1 November 2018. The research
collaboration was established in June 2015 with Orano Med (formerly known as
AREVA Med) to develop and investigate a next-generation targeted alpha therapy,
comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) and lead-212
(212Pb), for the treatment of B-cell malignancies.

The preclinical studies investigated the dose-dependent efficacy and
tolerability of 212Pb-NNV003 in human cell and mouse models of chronic
lymphocytic leukaemia (CLL) and Burkitt’s lymphoma (a type of non-Hodgkin’s
lymphoma, NHL). In the studies, 212Pb-NNV003 was found to be well tolerated and
led to a 90-100% survival rate in mouse models of CLL and NHL.

Abstract 1371

Abstract title:

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177lu-Lilotomab
Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Authors:

G.E. Rødland et al.

The poster describes results from a preclinical study aimed at identifying
possible drug combinations involving Betalutin® in two aggressive,
radioimmunotherapy-resistant diffuse large B-cell lymphoma (DLBCL) cell lines.
The study identified cell cycle kinase inhibitors as promising partners for
combination treatment of aggressive DLBCL with Betalutin®, warranting further
exploration in preclinical models.

Both abstracts are available at http://www.hematology.org/Annual-Meeting/ and
the posters have been published on the Nordic Nanovector website -
http://www.nordicnanovector.com/what-we-do/scientific-publications/scientific
-posters

About ASH

The ASH annual meeting is the premier event for scientific exchange in the field
of haematology, attracting more than 20,000 attendees from all over the world.
Typically, more than 5,000 scientific abstracts are submitted each year, and
more than 3,000 abstracts are accepted for oral and poster presentations through
an extensive peer review process.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 28.7 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These
statements are based on management’s current expectations and are subject to
uncertainty and changes in circumstances, since they relate to events and depend
on circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Tradin

http://www.netfonds.no/quotes/release.php?id=20181204.OBI.20181204S3

[F-Tosca]

From ASH with love
Posteren med Nano og oranomed
Pb212-NNV-003
[http://www.nordicnanovector.com/sites/default/files/link-documents/poster-ash-2018-oranomed-web.pdf ]

[tusekakk]

Fra børsmelding 16. November:

NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.

Fra børsmelding i dag:

NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 28.7 billion by 2026.

[F-Tosca]

Oppdatert info, med andre ord.
Edit, sjekk denne.
https://www.marketwatch.com/press-release/biotechnologies-are-improving-as-the-global-oncology-market-grows-2018-12-03

[Nocturne]

Vet du om Nano får noe penger for dette studiet av Orano? Hva er greia? Og vet du om Orano bare kan kjøpe ut denne delen av pipeline?

[larosaleda]

Nordic Nanovector has the option to license any resulting ARCs for further development and AREVA Med has the option to license the use of CD37 -targeting antibodies for its own purposes.

Fra Newsweb

[InVivo]

Ifølge Erna går visstnok innrulleringen til ARCHER-1 over all forventning!

Isåfall er det på linje med mine tidligere prediksjoner.

[Oilimp]

Ifølge Erna går visstnok innrulleringen til ARCHER-1 over all forventning!

Hvor har @Senior den infoen fra?
Det høres meget bra ut da!

[F-Tosca]

Sorry, sovna. Så at @larosaleda hadde svart. Prøver å lure en datamaskin. Min egen.

[InVivo]

Hvor har @Erna den infoen fra?
Det høres meget bra ut da!

Har en mistanke om at der var fyllerør. Han påstår at han jobber på St Olav.
Men det er jo lov å håpe;)

[coyw]

Fyllerør på en tirsdag formiddag? Litt tidlig eller?

[studenten86]

Tiden fra første klinikk var åpen for rekruttering, til første pasient var behandlet var svært kort. Så vi har vel alle en indikasjon på at rekrutteringshastigheten ikke er så værst. Men også greit å huske, det er ikke så mange klinikker som rekrutterer til det studiet enda.

[InVivo]

Det rekrutteres vel ved alle store sykehus i Norge PDD?

[storm]

om så stemmer er vel dette taushetsbelagt informasjon vil jeg tro? Vi får se hva Erna svarer…

[InVivo]

Tja, det spørs jo hvor nærme han står kilden det.

Tok fly for et par uker siden og overhørt en samtale mellom to typer, fikk en huch på at de var leger eller forskere, de diskuterte BergenBio, Tarfovax mefl.
Fikk ikke med meg alt de sa, og tro meg, jeg hadde spisse ører;) Onocoinvent og Bruland og Larsen ble også nevnt, i positive ordlag.

Men klart, hadde jeg plukket opp noe sensitivt derfra og gjengitt det her, så hadde vel ikke det vært mitt problem.

[F-Tosca]

Jepp, de popper opp, om man googler litt.